Zurück zu Projekte

25758.1 PFLS-LS

Developing a therapeutic vaccination targeting pruritus in equine

Zusammenfassung

Developing a therapeutic vaccination targeting pruritus in equine

Weitere Texte

Abstract

This research project#s objective is to evaluate a potential benefit of blocking IL-31- mediated pruritus in allergic dermatitis of the horse. The most common allergic dermatitis of horses is the so-called insect bite hypersensitivity (IBH), an allergy against insect bites. Therefore, we will develop a therapeutic vaccine against aiming at inducing anti-IL-31 auto-antibodies. This vaccine will be compared against a monotherapy of the already existing vaccine eIL-5-VLP and a combination therapy of eIL-5-VLP and eIL-31- VLP in a placebo controlled randomized double blind phase II study. Furthermore, the vaccine production will be optimized, the clinical proof of efficacy will be obtained, and long-term safety profiles of the vaccines will be studied.

Beteiligte

Antonia Gabriel

Wirtschaftspartner

antonia@evax.ch

Evax AG Antonia Gabriel Hörnlistrasse 3 9542 Münchwilen TG CH

Thomas Kündig

Kontaktperson

thomas.kuendig@usz.ch

USZ Universitätsspital Zürich Dermatologie Thomas Kündig Gloriastrasse 31 8091 Zürich ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2017-03-31
Enddatum
2019-11-30
Bewilligte Gesamtkosten
CHF 374584.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%